

## SPECIALTY GUIDELINE MANAGEMENT

### ASPARLAS (calaspargase pegol - mknl)

#### POLICY

#### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

##### A. FDA-Approved Indication

Asparlas is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years.

##### B. Compendial Uses

1. Lymphoblastic lymphoma (managed in the same manner as ALL)<sup>2,3</sup>
2. Acute lymphoblastic leukemia (ALL) as a substitute for pegaspargase in patients 21 years and younger for more sustained asparaginase activity<sup>2</sup>
3. Pediatric acute lymphoblastic leukemia (ALL) as a substitute for pegaspargase in patients age 1 month to 21 years for more sustained asparaginase activity<sup>2</sup>

All other indications are considered experimental/investigational and not medically necessary.

#### II. CRITERIA FOR INITIAL APPROVAL

Authorization of 12 months may be granted for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma when all of the following criteria are met:

- A. The requested medication will be used in conjunction with multi-agent chemotherapy.
- B. The member is 21 years of age or younger.

#### III. CONTINUATION OF THERAPY

Authorization of 12 months total may be granted for continued treatment in members requesting reauthorization for an indication listed in Section II when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

#### IV. REFERENCES

1. Asparlas [package insert]. Boston, MA: Servier Pharmaceuticals LLC; October 2022.
2. NCCN Drugs & Biologics Compendium® © 2023 National Comprehensive Cancer Network, Inc. Available at <http://www.nccn.org>. Accessed June 2, 2023.
3. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Acute Lymphoblastic Leukemia. Version 1.2022. [http://www.nccn.org/professionals/physician\\_gls/pdf/all.pdf](http://www.nccn.org/professionals/physician_gls/pdf/all.pdf). Accessed June 2, 2023.

| Reference number |
|------------------|
| 2833-A           |

4. Int J Radiat Oncol Biol Phys. (2018). *Lymphoblastic Lymphoma: Guidelines From the International Radiation Oncology Group (ILROG)*. 2018 Nov 1; 102(3):508-514.  
<https://doi.org/10.1016/j.ijrobp.2018.05.078>